Versatope Therapeutics

Versatope Therapeutics is a clinical-stage biotechnology company developing vaccines and therapeutics using a proprietary nanovesicle platform. Their lead program, VT-105, is a universal flu vaccine that has a clear path to inflection and exit. The company is now raising its first seed round of $6M for a Phase I clinical study. It is supported by over $20M in NIH funding to date, additional non-dilutive funding pending, a successful IND with FDA allowance, and nine global patents.